Randomized Trial of Adjuvant Immunotherapy with an Allogeneic Melanoma Vaccine for Patients with Intermediate Thickness, Node Negative Malignant Melanoma (T3N0M0), Phase III.

Adjuvant vaccine immunotherapy of resected, clinically node-negative melanoma: long-term outcome and impact of HLA class I antigen expression on overall survival

WE Carson;JM Unger;J Sosman;LE Flaherty;RJ Tuthill;M Park;MJ Porter;PI Terasaki;JA Thompson;RA Kempf;M Othus;A Ribas;VK Sondak Cancer Immunology Research 2(10):981-987;

PMid: PMID24994597 | PMC number: PMC4185232

Comparison of survival outcomes among cancer patients treated in and out of clinical trials

J Unger;W Barlow;DP Martin;S Ramsey;M Leblanc;R Etzioni;D Hershman Journal of the National Cancer Institute 106(3):dju002; 2014 Mar 13 [Epub ahead of print];

PMid: PMID24627276 | PMC number: PMC3982777

Significant impact of HLA class I allele expression on outcome in melanoma patients treated with an allogeneic melanoma cell lysate vaccine. Final analysis of SWOG-9035.

VK Sondak;J Sosman;JM Unger;PY Liu;J Thompson;R Tuthill;R Kempf;L Flaherty Proc of the American Society of Clinical Oncology 23:707 (#7501)

HLA D3(7) confers a poor prognosis in intermediate thickness (1.5-4.0mm) melanoma: serotyping of 553 patients on SWOG 9035.

JA Sosman;J Unger;JE Lee;P Liu;L Flaherty;VK Sondak Proc of the American Society of Clinical Oncology 22:710(#2856)

Results of clinical trials with an allogenic melanoma tumor cell lysate vaccine: melacine

VK Sondak;JA Sosman Seminars in Cancer Biology 13(6):409-415

Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: Overall results of a randomized trial of the Southwest Oncology Group

VK Sondak;PY Liu;RJ Tuthill;RA Kempf;JM Unger;JA Sosman;JA Thompson;GR Weiss;BG Redman;JG Jakowatz;RD Noyes;LE Flaherty Journal of Clinical Oncology 20(8):2058-2066

Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: Impact of HLA class I antigen expression on outcome.

JA Sosman;JM Unger;PY Liu;LE Flaherty;MS Park;RA Kempf;JA Thompson;PI Terasaki;VK Sondak Journal of Clinical Oncology 20(8):2067-2075

HLA-A2 and/or HLA-C3 expression defines a subset of T3N0 melanoma patients with improved overall survival from melacine vaccine: an updated analysis of SWOG 9035.

JA Sosman;JM Unger;PY Liu;R Kempf;L Flaherty;J Thompson;VK Sondak Proc of the American Society of Clinical Oncology 21:340a(#1359)

Significant impact of HLA classI alleles on outcome in T3NO melanoma patients treated with melacine (MEL): an allogeneic melanoma cell lysate vaccine: prospective analysis of Southwest Oncology Group (SWOG)-9035.

JA Sosman;JM Unger;PY Liu;L Flaherty;R Kempf;J Thompson;V Sondak Proc of the American Society of Clinical Oncology 20:351a(#1402)

Adjuvant therapy with an allogeneic tumor vaccine in T3N0M0 melanoma (SWOG-9035)

VK Sondak;PY Liu;RJ Tuthill;RA Kempf;JM Unger;JA Sosman;JA Thompson;GR Weiss;BG Redman;LE Flaherty Proc of the Melanoma at the Millennium :79

SWOG-9035: adjuvant therapy of intermediate-thickness node-negative melanoma with an allogeneic tumor vaccine.

VK Sondak;PY Liu;RJ Tuthill;RA Kempf;JM Unger;JA Sosman;JA Thompson;GR Weiss;BG Redman;JG Jakowatz;RD Noyes;LE Flaherty Journal of Immunotherapy 23(5):600

Class I HLA serotyping in T3NO melanoma patients entered onto SWOG 9035: a phase III trial of melacine TM (allogeneic tumor lysate vaccine) vs observation.

JA Sosman;JM Unger;PY Liu;L Flaherty;J Thompson;VK Sondak Journal of Immunotherapy 23(5):605

Adjuvant therapy for melanoma.

VK Sondak;JA Wolfe Current Opinion in Oncology 9:189-204